Log in

you haven't confirmed your email address yet. resend confirmation email

Forget your password? Reset password

Enter Phone Number

Enter the code

Almost done!

We just sent a four digit code to your mobile number. Enter it here to log in!

Didn't receive the code?Re-send
Or log in with your password instead

or register with

Facebook

Google

Don't have an account? Register here.

Join the community

I have read and understand the oneSCDvoice privacy policy and terms of use, and I confirm that I am over 12 years old.

Almost done!

We just sent a four digit code to your mobile number. Enter it here to log in!

Please Wait!!!

Didn't receive the code?Re-send
Or log in with your password instead

or register with

Facebook

Google

Already have an account? Log in.

Social Wall
Trusted Resources
SCD Education

Or register here

Social Wall
Trusted Resources
SCD Education
My Account

contact us

have a question, issue or just some feedback for us? we're here for you.

what can we help you with?

let us know how we can help

suggest a poll

you must have an account to suggest polls.

join now

DISCLAIMER

The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.

compose your message

to*

from*

subject

message

message sent

email sent successfully

Trusted Resources: News & Events

Latest announcements and gatherings

Business
Clinical Trials and Research
Happenings
People
Spotlight

Back to News & Events / Clinical Trials And Research

SUSTAIN Clinical Trial Results Show Crizanlizumab Reduced Sickle Cell–Related Pain Crises

Results from the Phase 2 SUSTAIN clinical trial demonstrated that crizanlizumab (SEG101, Selexys Pharmaceuticals, Novartis), an anti-P-selectin antibody, reduced by 45.3% the median annual rate of sickle cell-related pain crises (SCPC), compared to placebo in patients with or without hydroxyurea therapy, a drug used to reduce the rate of painful attacks in sickle-cell disease (SCD). Crizanlizumab also significantly extended time to first and second SCPC, the researchers reported.

These results were recently presented at the ASH Annual Meeting and Exposition, and published in the New England Journal of Medicine.

SUSTAIN Clinical Trial Results Show Crizanlizumab Reduced Sickle Cell–Related Pain Crises

Source: https://sicklecellanemianews.com/2016/12/13/crizanlizumab-reduces-sickle-cell-related-pain-crises/

Discuss in Social Wall

Twitter

Share to SCDteam

+myBinder

send a message

send to:
subject:
message:

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Log in

Enter the code

Join the community

Trusted Resources Home

Education & Research

People & Places

News & Events

Videos & Visuals

Community Center

SUSTAIN Clinical Trial Results Show Crizanlizumab Reduced Sickle Cell–Related Pain Crises

Related Content

Powered by